Every Form 4 that Hyperliquid Strategies Inc (PURR) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow PURR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PURR filings page.
Hyperliquid Strategies Inc (PURR) CFO Brett Douglas Beldner acquired an award of 82,781 restricted stock units on September 28, 2026. The units are scheduled to vest over a three-year period. His reported direct position following the award was 536,244 shares.
Hyperliquid Strategies Inc (PURR) CEO and director David Ira Schamis reported an award of 248,344 shares represented by restricted stock units on September 28, 2026. The units are scheduled to vest over three years, with one-third vesting on September 28, 2027, September 28, 2028 and September 28, 2029. His reported direct holdings after the transaction were 800,666 shares.
For Hyperliquid Strategies Inc (PURR), Chief Operating Officer Jeroen Nieuwkoop reported an award of 82,781 restricted stock units held indirectly through SBR Limited on September 28, 2026. The units are scheduled to vest over three years, with one-third vesting on September 28, 2027, September 28, 2028, and September 28, 2029.
Hyperliquid Strategies Inc (PURR) director Robert E. Diamond Jr. reported acquiring 832,750 shares of common stock on September 17, 2026 in an "other" transaction classified as a restructuring. The shares were received as a pro rata distribution from Rorschach Capital LLC, where he is a non-managing member, bringing his directly reported holdings to 1,510,339 shares. No Rule 10b5-1 trading plan is reported for this transaction.
Hyperliquid Strategies Inc (PURR) reported that CEO and director David Ira Schamis acquired 416,013 shares of Common Stock on September 17, 2026 through an "other" type transaction. The shares were received as a pro rata distribution from Rorschach Capital LLC, and he now holds 552,322 shares directly.
No Rule 10b5-1 trading plan is reported for this transaction, and the shares were transferred at a stated price of $0.00 per share, reflecting an internal distribution rather than an open-market purchase.
Hyperliquid Strategies Inc (PURR) director Jeffrey Tuder reported acquiring 231,692 shares of common stock on September 17, 2026 through a pro rata distribution from Rorschach Capital LLC, where he is a non-managing member. Following this transaction, he holds 272,481 shares directly and 8,188 shares indirectly via Tremson Capital Management, LLC, for which he disclaims beneficial ownership except for his pecuniary interest. No Rule 10b5-1 trading plan is reported.
Hyperliquid Strategies Inc (PURR) director Jeffrey Tuder reported acquiring three blocks of warrants to purchase 272,578 shares of common stock each, with exercise prices of $9.375, $12.50, and $18.75 per share. The warrants become exercisable on December 2, 2025 and expire on December 2, 2030. The reporting person states these warrants were received in a pro rata distribution from Rorschach Capital LLC, where he is a non-managing member, and no Rule 10b5-1 trading plan is reported.
Hyperliquid Strategies Inc (PURR) director Robert E. Diamond Jr. reported acquiring three blocks of warrants to purchase Common Stock on August 31, 2026, in an entity restructuring coded as an "other acquisition or disposition." Each block covers 1,253,860 warrants, received via a pro rata distribution from Rorschach Capital LLC, of which he is a non-managing member. The warrants have exercise prices of $9.375, $12.50, and $18.75 per share, are first exercisable on December 2, 2025, and expire on December 2, 2030. No Rule 10b5-1 trading plan is reported.
Hyperliquid Strategies Inc (PURR) director and CEO David Ira Schamis reported the acquisition of three blocks of 537,585 warrants each on August 31, 2026, through an entity restructuring transaction. Each warrant block is exercisable for common stock from December 2, 2025 and expires on December 2, 2030, with exercise prices of $9.375, $12.50, and $18.75 per share, respectively. The warrants were received as a pro rata distribution from Rorschach Capital LLC, where he is a non‑managing member, and no Rule 10b5‑1 trading plan is reported.
LEIBOWITZ LAWRENCE E reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Lawrence E. Leibowitz received an equity grant rather than cash compensation. On July 1, 2026, he was awarded 2,117 shares of Common Stock at $0.00 per share, electing to take pay in stock under the company’s 2025 Equity Incentive Plan.
After this grant, he directly holds 85,980 shares of Hyperliquid Strategies Inc common stock. This was a non-cash, compensation-related award, not an open‑market purchase or sale.
Rosengren Eric S reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Eric S. Rosengren increased his direct holdings through an equity compensation grant. On July 1, 2026, he received 4,764 shares of common stock at $0.00 per share as compensation in lieu of cash under the 2025 Equity Incentive Plan. After this grant, he directly holds 76,800 common shares, and no derivative securities are reported in this filing.
Hyperliquid Strategies Inc director Thomas C. King received a grant of 4,764 shares of common stock on July 1, 2026. The filing states he elected to take this equity instead of cash under the company’s 2025 Equity Incentive Plan, so no purchase occurred in the market.
After this award, King directly holds a total of 76,800 common shares. This is a routine compensation-related acquisition, reflecting additional equity-based pay rather than a discretionary open-market trade.
Hyperliquid Strategies Inc director Nailesh Bhatt reported receiving a stock-based compensation award. On July 1, 2026, he acquired 1,588 shares of Common Stock at $0.00 per share, classified as a grant or award rather than an open-market trade.
According to the filing, Bhatt elected to receive these shares as compensation in lieu of cash under Hyperliquid Strategies’ 2025 Equity Incentive Plan. Following this award, he directly holds 46,914 shares of the company’s common stock, reflecting increased equity-based compensation and no reported sales or dispositions in this filing.
Nieuwkoop Jeroen reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc reported that SBR Limited, a Hong Kong company controlled by Chief Operating Officer Jeroen Nieuwkoop, received 421,623 restricted stock units (RSUs) of common stock as of June 23, 2026 under an executive placement agreement.
Of these RSUs, 271,923 are scheduled to vest ratably on an annual basis over three years starting on December 2, 2026, and 149,700 are scheduled to vest ratably over three years starting on May 5, 2027. Following the transactions, Nieuwkoop also holds 31,840 common shares directly and 421,623 common shares indirectly through SBR Limited.
Beldner Brett Douglas reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc CFO Brett Douglas Beldner reported an equity compensation grant of 421,623 restricted stock units (RSUs) of common stock at a price of $0.0000 per unit in connection with an employment agreement.
The filing states that 271,923 RSUs vest ratably on an annual basis over 3 years commencing on December 2, 2026, and 149,700 RSUs vest ratably on an annual basis over 3 years commencing on May 5, 2027. Following this grant, Beldner directly holds 453,463 shares/RSUs of the company’s common stock.
Bhatt Nailesh reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Bhatt Nailesh received 2,455 restricted shares of common stock as compensation. The shares were granted on April 1, 2026 at a stated price of $0.00 per share, reflecting an equity award rather than a market purchase.
According to the footnote, Nailesh elected to receive these restricted shares instead of cash under Hyperliquid Strategies Inc's 2025 Equity Incentive Plan. After this award, he directly holds 45,326 shares of common stock. This is a routine director compensation grant, not an open-market buy or sale.
Rosengren Eric S reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Eric S. Rosengren received a grant of 7,367 restricted shares of common stock as compensation in lieu of cash under the company’s 2025 Equity Incentive Plan. Following this award, he directly holds 72,036 shares of Hyperliquid Strategies common stock.
KING THOMAS C. reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Thomas C. King received a grant of 7,367 restricted shares of common stock as compensation in lieu of cash. The award was made under the company’s 2025 Equity Incentive Plan and increased his directly held common stock to 72,036 shares.
LEIBOWITZ LAWRENCE E reported acquisition or exercise transactions in this Form 4 filing.
Hyperliquid Strategies Inc director Lawrence E. Leibowitz received a grant of 3,274 restricted shares of common stock. The shares were taken as compensation in lieu of cash under the company’s 2025 Equity Incentive Plan and were reported at a price of $0.00 per share.
After this award, Leibowitz directly holds 83,863 shares of common stock. This is a routine, compensation-related equity grant rather than an open-market purchase or sale.
Hyperliquid Strategies Inc CEO and director David Ira Schamis reported an equity award in the company’s common stock. On February 9, 2026, he acquired 40,789 shares at a price of $0 through a grant classified as a “grant, award, or other acquisition.”
After this award, he directly beneficially owned 136,309 shares of common stock. The grant represents restricted stock units scheduled to vest over three years, with one-third vesting on December 2, 2026, one-third on December 2, 2027, and one-third on December 2, 2028.
Hyperliquid Strategies Inc director Jeffrey Tuder reported an equity award. On February 9, 2026, he acquired 40,789 shares of common stock at a price of $0 through a grant classified as a restricted stock unit award. These restricted stock units are scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028. After this grant, he holds 40,789 shares directly and 8,188 shares indirectly through Tremson Capital Management, LLC, for which he disclaims beneficial ownership except for his pecuniary interest.
Hyperliquid Strategies Inc director Albert D. Dyrness reported receiving a grant of 40,789 restricted stock units (RSUs) of common stock on February 9, 2026 at a price of $0 per unit. Following this award, he beneficially owns 41,671 common shares.
The RSUs are scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028. The filing characterizes the transaction as a grant, award, or other acquisition of shares held directly.
Hyperliquid Strategies Inc director Robert E. Diamond Jr. received a grant of 40,789 shares of common stock on February 9, 2026 as a stock award, at a stated price of $0 per share. After this grant, he directly beneficially owns 677,589 common shares.
The award represents restricted stock units scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028. This filing reports an equity-based compensation grant rather than an open-market stock purchase or sale.
Hyperliquid Strategies Inc director Nailesh Bhatt received a stock award of 40,789 shares of common stock on February 9, 2026. The filing shows this as an acquisition at a price of $0 per share, bringing his directly held stake to 42,871 shares.
The award represents restricted stock units that are scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028. This structure ties Bhatt’s compensation to the company’s longer-term performance and continued service.
Hyperliquid Strategies Inc director Eric S. Rosengren acquired 40,789 shares of common stock on February 9, 2026 through a stock grant. This award was made at a price of $0 per share and increased his beneficial ownership to 64,669 shares held directly.
The grant represents restricted stock units that are scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028. This creates a long-term incentive that ties his compensation to future company performance.
Hyperliquid Strategies Inc director Thomas C. King reported an acquisition of company stock through an equity grant. On February 9, 2026, he received 40,789 shares of Common Stock at a price of $0.00 per share as a grant, increasing his directly held position to 64,669 shares.
The grant represents restricted stock units that are scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028, aligning potential ownership with longer-term service.
Hyperliquid Strategies Inc director Lawrence E. Leibowitz reported an equity award of 40,789 shares of common stock, recorded as a grant under a Form 4 filing. The award is in the form of restricted stock units that carry a price of $0 per unit.
The filing shows he beneficially owns 80,589 common shares after this grant. These restricted stock units are scheduled to vest over three years, with one-third vesting on each of December 2, 2026, December 2, 2027, and December 2, 2028.
Hyperliquid Strategies Inc reported that chief operating officer Jeroen Nieuwkoop received 31,840 shares of common stock in a zero‑price transaction on December 4, 2025. The filing shows this as a direct holding, giving him beneficial ownership of 31,840 shares after the transaction.
The transfer stems from the company’s recently completed business combination. On December 2, 2025, Hyperliquid Strategies completed a business combination under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc. and related entities. In connection with that closing, Rorschach Capital LLC received 6,580,800 shares of Hyperliquid Strategies common stock and subsequently distributed 31,840 of those shares to Mr. Nieuwkoop as a member of Rorschach Capital LLC.
Hyperliquid Strategies Inc director Mr. Diamond reported acquiring 636,800 shares of the company’s common stock in a transaction dated December 4, 2025. The shares were distributed to him by Rorschach Capital LLC, of which he is a member, after that entity received 6,580,800 common shares at the closing of Hyperliquid’s previously announced business combination with Sonnet BioTherapeutics Holdings, Inc. and related parties.
Following this distribution, Mr. Diamond beneficially owns 636,800 shares of Hyperliquid Strategies Inc common stock, held directly.
Hyperliquid Strategies Inc director reported receiving 23,880 shares of common stock through a distribution from Rorschach Capital LLC. Following this transaction, the director beneficially owns 23,880 common shares directly.
The disclosure explains that on December 2, 2025, the company completed a previously announced business combination under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc. and related entities. In connection with the closing, Rorschach Capital LLC received an aggregate of 6,580,800 shares of Hyperliquid Strategies common stock, and on December 4, 2025 it distributed 23,880 shares to Mr. Rosengren, a member of Rorschach Capital LLC.
Hyperliquid Strategies Inc. director reported receiving 23,880 shares of common stock on December 4, 2025, as disclosed in a Form 4 insider filing. The shares were acquired through a distribution from Rorschach Capital LLC, where the director is a member, and are shown as directly owned following the transaction.
The distribution came shortly after the completion of Hyperliquid Strategies Inc.'s previously announced business combination on December 2, 2025, under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC, TBS Merger Sub Inc. and Rorschach Merger Sub, LLC. In connection with that closing, Rorschach Capital LLC received an aggregate 6,580,800 shares of Hyperliquid Strategies common stock, a portion of which was later distributed to the director.
Hyperliquid Strategies Inc director Nailesh Bhatt reported receiving 2,082 shares of the company’s common stock on December 2, 2025. After this transaction, she beneficially owns 2,082 common shares in a direct capacity.
The filing explains that the shares were issued in connection with the closing of a previously announced business combination between Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Ms. Bhatt received the shares in exchange for certain Sonnet securities she held before the transaction closed.
Hyperliquid Strategies Inc reported that a director acquired 39,800 shares of common stock on December 4, 2025. The transaction was coded “J” and reflects an acquisition, leaving the director with 39,800 shares beneficially owned in direct form.
This acquisition came from a distribution by Rorschach Capital LLC. Two days earlier, on December 2, 2025, the Company completed a previously announced business combination under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc. and related entities, in which Rorschach Capital LLC had received 6,580,800 shares of Hyperliquid Strategies common stock.
Hyperliquid Strategies Inc reported that its chief executive officer and director, Mr. Schamis, acquired 95,520 shares of common stock on December 4, 2025 through a distribution from Rorschach Capital LLC.
This distribution followed the completion of Hyperliquid’s previously announced business combination on December 2, 2025, under a Business Combination Agreement with Sonnet BioTherapeutics Holdings, Inc., Rorschach I LLC and other entities, in which Rorschach Capital LLC received 6,580,800 company shares. After the reported transaction, the officer beneficially owns 95,520 shares directly.
Hyperliquid Strategies Inc’s chief financial officer reported receiving 31,840 shares of common stock, which are now held as a direct ownership position. The shares were acquired on December 4, 2025 and recorded as an acquisition transaction.
The filing explains that, in connection with the closing of a previously announced business combination on December 2, 2025, Rorschach Capital LLC received 6,580,800 shares of Hyperliquid Strategies Inc common stock. Two days later, Rorschach Capital LLC distributed 31,840 shares of that stock to Mr. Beldner, reflecting his interest as a member of Rorschach Capital LLC.